Healthcare Biopharmaceuticals Market

Global Healthcare Biopharmaceuticals Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2023-2029- The market will expand due to the increasing prevalence of chronic diseases, increasing investment in research and development by pharmaceutical companies, and growing focus on rare diseases and orphan drugs.

Global Healthcare Biopharmaceuticals Market is valued at USD 472.5 Billion in 2022 and it is expected to reach USD 783.8 Billion by 2029 with a CAGR of 7.5% over the forecast period.

Scope of Global Healthcare Biopharmaceuticals Market Report-

Healthcare Biopharmaceuticals are pharmaceuticals products that are manufactured using biological processes and techniques. These products are developed through the use of living organisms or their derivatives, such as recombinant DNA technology, to produce drugs and other medical products. Biopharmaceuticals have revolutionized the treatment of various diseases, including cancer, diabetes, and autoimmune disorders.

Biopharmaceuticals have been around since the 1980s when the first recombinant DNA technology was developed. This technology enabled researchers to manipulate the genetic code of living organisms to produce proteins and other molecules that could be used to treat diseases. Biopharmaceuticals are primarily used by healthcare providers, such as hospitals, clinics, and pharmacies, as well as by patients who require these products to treat their medical conditions.

 

Covid-19 Impact on the Global Healthcare Biopharmaceuticals Market:

The Covid-19 pandemic has had a significant impact on the global healthcare biopharmaceuticals market. The demand for biopharmaceuticals has increased due to the pandemic as the industry has been playing a vital role in developing vaccines, therapies, and diagnostic tests for Covid-19. However, the pandemic has also caused disruptions in the supply chain of the industry due to lockdowns, travel restrictions, and reduced manufacturing capacity, leading to delays in drug development and shortages of essential medicines.

 

Key Players of Global Healthcare Biopharmaceuticals Market Report-

Some major key players for the global Healthcare Biopharmaceuticals market report cover prominent players like

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• Hoffmann-La Roche AG
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Allergan plc
• Alexion Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• Biogen Idec Inc.
• BioMarin Pharmaceutical Inc.
• Eisai Co. Ltd.
• Incyte Corporation
• Ipsen S.A.
• Jazz Pharmaceuticals plc
• Kyowa Hakko Kirin Co. Ltd.
• Mallinckrodt Pharmaceuticals
• Mylan N.V.
• Neurocrine Biosciences Inc.
• Ono Pharmaceutical Co. Ltd.
• Seattle Genetics nc.
• Shire plc
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.
• Vertex Pharmaceuticals Incorporated
• and others.

Global Healthcare Biopharmaceuticals Market Segmentation:-

By Product Type:

• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Gene Therapy
• Cell Therapy
• Other

By Application:

• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other

By End-User:

• Hospitals
• Clinics
• Research Institutes
• Others

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Market Drivers:

Increasing prevalence of chronic diseases: The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is a major factor driving the growth of the global healthcare biopharmaceutical market. For example; the American Cancer Society reports that cancer is the second leading cause of death in the United States, with an estimated 1.9 million new cancer cases and over 600,000 cancer deaths in 2021.

These diseases require long-term treatment and management, creating a high demand for innovative therapies and drugs. Biopharmaceuticals offer several advantages over traditional small-molecule drugs, such as high specificity, potency, and fewer side effects. As a result, biopharmaceuticals are becoming an increasingly popular choice for the treatment of chronic diseases.

Increasing investment in research and development by pharmaceutical companies: Biopharmaceuticals are complex and require extensive research and development to bring new drugs to market. Pharmaceutical companies are investing heavily in R&D to develop new drugs and therapies, which is leading to the discovery of new targets and biomarkers for various diseases.

The development of advanced biologics and biosimilars requires significant investments in clinical trials, regulatory compliance, and manufacturing. Additionally, a report by EvaluatePharma indicates that the global R&D spend on prescription drugs is expected to reach $213 billion by 2024, up from $181 billion in 2020.

Market Restraints:

Intellectual property rights and patent expiry issues: Biopharmaceuticals are expensive to develop and require significant investments in research and development. Companies rely on patent protection to recoup their investments and generate revenue. However, as patents expire, generic and biosimilar versions of the drugs become available, leading to increased competition and lower prices. This can significantly impact the revenue of the original drug developer.

According to EvaluatePharma, biologic drugs with sales of over $250 billion are expected to lose patent protection by 2025, leading to the entry of biosimilars and resulting in significant revenue losses for the original drug manufacturers. Additionally, patent litigation and challenges to intellectual property rights can lead to costly legal battles, further impacting the profitability of biopharmaceutical companies.

Opportunity Factors:

• Rising demand for personalized medicine.
• Increasing adoption of biosimilars.
• Emerging markets in Asia-Pacific and Latin America.
• Growing focus on rare diseases and orphan drugs.
• Advancements in manufacturing technologies such as continuous bioprocessing and single-use systems.

Market Trend:

Product and Technology Development:

Development of gene therapies and cell therapies, increasing use of artificial intelligence and machine learning in drug development, focus on precision medicine and biomarkers, and the advancements in drug delivery systems.

Customer Trends:

Increasing preference for self-administration and home-based care, growing demand for convenient and affordable healthcare, focus on patient-centric healthcare and shared decision-making, and increasing awareness about the benefits of biologics and biosimilars.

Market Competition Nature:

Key market players in the healthcare biopharmaceuticals market are adopting various strategies to stay competitive. In the past, many companies have focused on developing blockbuster drugs and acquiring smaller companies to expand their portfolio. In the future, companies are expected to continue investing heavily in research and development, partnering with other companies to bring new drugs to market, and focusing on niche markets such as rare diseases and oncology. Some companies may also explore new manufacturing technologies and use data analytics to optimize their supply chains and reduce costs.

Geography Analysis:

North America:

The North American healthcare biopharmaceutical market is primarily driven by factors such as increasing investment in R&D, rising prevalence of chronic diseases, and favorable government initiatives to promote biopharmaceuticals. The region has a highly developed healthcare infrastructure and a large patient population suffering from chronic diseases such as cancer, diabetes, and cardiovascular diseases, which is driving the demand for biopharmaceuticals. According to the Centers for Disease Control and Prevention (CDC), chronic diseases cause death and disability in the United States, accounting for approximately 7 out of 10 deaths each year.

In addition, rising investments in research and development by pharmaceutical companies and government agencies are also contributing to the growth of the market. For example; the National Institutes of Health (NIH) in the United States provides funding for research and development of new biopharmaceutical drugs. Pharmaceutical companies such as Merck & Co., AbbVie, and Amgen are also investing heavily in research and development to develop new biopharmaceutical drugs.

Europe:

Europe is a significant market for healthcare biopharmaceuticals due to its high adoption of biologics and biosimilars. According to a report by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European pharmaceutical market was valued at €186 billion in 2020. The report also notes that the biopharmaceuticals segment is growing faster than the overall pharmaceutical market and is expected to continue to grow in the coming years.

Several factors are driving the growth of the healthcare biopharmaceuticals market in Europe, including the increasing prevalence of chronic diseases, the aging population, and the high demand for innovative therapies. According to the World Health Organization, cancer is the second leading cause of death in Europe, accounting for 26% of all deaths.

Revenue generation model:

The revenue generation model for healthcare biopharmaceuticals typically involves the development and commercialization of new drugs and therapies, as well as the production and sale of existing products. The industry is highly regulated, with strict requirements for clinical trials and FDA approval, which can result in significant costs and longer development timelines.

Supply chain model:

The supply chain model for healthcare biopharmaceuticals involves multiple stages, including research and development, clinical trials, manufacturing, distribution, and marketing. Companies often partner with contract research organizations (CROs) and contract manufacturing organizations (CMOs) to help streamline these processes and bring products to market more efficiently

Value chain model:

The value chain model for healthcare biopharmaceuticals involves the creation of value at each stage of the process, from initial research and development to commercialization and distribution. Companies that can effectively navigate these stages and create high-value products that meet the needs of patients and healthcare providers can generate significant revenue and capture market share.

Key Benefits of Global Healthcare Biopharmaceuticals Market Report–

• Global Healthcare Biopharmaceuticals Market report covers in-depth historical and forecast analysis.
• Global Healthcare Biopharmaceuticals Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Healthcare Biopharmaceuticals Market report helps to identify opportunities in the marketplace.
• Global Healthcare Biopharmaceuticals Market report covers extensive analysis of emerging trends and competitive landscape.